Bruce Booth - 01 Mar 2022 Form 4 Insider Report for Vigil Neuroscience, Inc. (VIGL)

Reporting relationship: Director
Issuer ticker: VIGL
Reported as of: 01 Mar 2022
Net transaction value: +$72,967
SEC form: 4
Accepted by SEC: 03 Mar 2022, 15:05:54 UTC
Prior SEC filing: 11 Jan 2022
Next SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Ommer Chohan, Attorney-in-Fact

Key filing fact

Bruce Booth filed Form 4 for Vigil Neuroscience, Inc. (VIGL) on 03 Mar 2022.

Key facts

This page summarizes Bruce Booth's Form 4 filing for Vigil Neuroscience, Inc. (VIGL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2022, 15:05.

Change

Previous filing in this sequence was filed on 11 Jan 2022.
Current net transaction value: +$72,967.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VIGL transaction Derivative

Stock Option Grant (Right to Buy)

Award

Transaction value: $72,967
Shares: +7,577
Change %
Price: $9.63
Shares after: 7,577
Date: 01 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,577
Exercise price: $16.13
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2022.

Footnote F2

This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.